Platelets—blood cells continuously produced from megakaryocytes mainly in the bone
marrow—are implicated not only in haemostasis and arterial thrombosis, but also in other …

Transcatheter aortic valve implantation (TAVI) or replacement has rapidly changed the
treatment of patients with severe symptomatic aortic stenosis. It is now the standard of care …

Background There have been ongoing efforts to understand when and how data from
observational studies can be applied to clinical and regulatory decision making. The …

Background Although current guidelines recommend dual antiplatelet therapy (DAPT) for 3
to 6 months following transcatheter aortic valve replacement (TAVR), there are no studies …

Background The incidence and predictors of 30‐day stroke after transcatheter aortic valve
replacement (TAVR) were derived from early studies investigating first‐generation devices …

Background The clinical predictors and sequelae of leaflet thrombosis (LT) following
transcatheter aortic valve replacement (TAVR) is still unclear. Therefore, our aim was to …

Objectives. To compare the incidence of mortality and complications between
nonagenarians and younger patients undergoing transcatheter aortic valve replacement …

Abstract Background The Antiplatelet Therapy for Patients Undergoing Transcatheter Aortic-
Valve Implantation (POPular TAVI) trial reported comparable composite endpoints of …

aortic valve replacement (TAVR) is a mature technology that has demonstrated either
noninferiority or superiority to surgical aortic valve replacement (SAVR) in all surgical risk …

Majority of patients undergoing TAVR have multiple comorbidities and are at increased risk
of ischemic and bleeding complications. In the absence of robust clinical evidence, there is …